Alliance Pharma reported lower Consumer Healthcare division revenues in 2024 as sales dipped for the Nizoral anti-dandruff line and Amberen menopause brand.
Alliance Pharma Posts Lower Full-Year Sales
UK-based Alliance Pharma reported a single-digit drop in Consumer Healthcare turnover ahead of a shareholder vote on the company's future ownership.
More from Earnings
• By
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.
• By
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.
• By
Key growth driver in consumer health and across Bayer’s sectors, says CEO Bill Anderson, is “dynamic shared ownership program” introduced in January 2024 to "reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes."
• By
UK-based consumer health giant reports organic sales growth of 5.0% in 2024 as gains for its power brands offset a softer cold & flu season, particularly in the US.
More from Strategy
• By
HBW Insight catches up with Maxwellia CEO Anna Maxwell to discuss her company's journey so far, and what she sees as the opportunities for Rx-to-OTC switch in UK women's health and beyond.
• By
Consumer uptake of Eroxon - the first FDA-approved OTC ED treatment available in the US - has been slower than expected, according to Haleon, which says its working with retailers to build awareness.
• By
The Swedish firm is plotting the path towards launching its ColdZyme virus-blocking spray in China and Japan, while efforts are also underway to find a partner for the North American market.